Mullings Julie
Community Matron, Tissue Viability and Infection Prevention Manchester University NHS Foundation Trust.
Br J Community Nurs. 2019 Sep 1;24(Sup9):S6-S11. doi: 10.12968/bjcn.2019.24.Sup9.S6.
Research has shown that leg ulcers represent the largest category of wound type treated within the UK. Venous leg ulcers are often classified as chronic wounds with increased protease levels causing the wound to become suspended in the inflammatory stage, which leads to delayed healing. If treatment choices are not evidence-based and appropriate regimens are not instigated early on in the wound care journey, the cost to both the patient and the healthcare service is substantial. Recent guidance from the National Institute of Health and Care Excellence (NICE) recommends UrgoStart (Urgo Medical) for treating venous leg ulcers as an adjunct therapy to the gold standard of compression therapy. Correct treatment choices must be made by clinicians using up-to-date relevant wound care knowledge. Evidence-based treatment algorithms and pathways can assist with correct product and therapy placement, assisting decision-making to improve patient outcomes. The present article describes a patient-centred leg ulcer pathway that embeds NICE guidance.
研究表明，腿部溃疡是英国治疗的最大伤口类型。静脉性腿部溃疡通常被归类为慢性伤口，蛋白酶水平升高导致伤口停滞在炎症阶段，从而导致愈合延迟。如果治疗选择缺乏循证依据，且在伤口护理过程中未尽早采用适当的治疗方案，那么对患者和医疗服务机构来说成本都将十分高昂。英国国家卫生与临床优化研究所（NICE）最近发布的指南推荐使用优格创（UrgoStart，优格医疗公司）作为辅助疗法，与压迫疗法这一黄金标准相结合来治疗静脉性腿部溃疡。临床医生必须运用最新的相关伤口护理知识做出正确的治疗选择。循证治疗算法和路径有助于正确选择产品和疗法，辅助决策以改善患者预后。本文介绍了一条以患者为中心的腿部溃疡治疗路径，该路径纳入了NICE指南。
